Estudo randomizado | Novo teste sanguíneo podem melhorar o rastreamento do câncer de próstata.
17 Ago, 2021 | 11:22hProstate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comunicado de imprensa: New blood test improves prostate cancer screening – Karolinska Institutet
Conteúdo relacionado: RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
Comentário no Twitter
Online first: #Prostatecancer #screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial #pcsm https://t.co/bijoJk8RbK pic.twitter.com/ENWEjqG3Kr
— The Lancet Oncology (@TheLancetOncol) August 13, 2021